Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 38372058)

  • 1. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    West HJ; Kim JY
    JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
    Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
    Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
    Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
    Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
    de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
    Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
    Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
    Blakely CM; Weder W; Bubendorf L; He J; Majem M; Shyr Y; Chaft JE
    Lung Cancer; 2023 Mar; 177():59-72. PubMed ID: 36736076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Chen LN; Wei AZ; Shu CA
    Ther Adv Med Oncol; 2023; 15():17588359231163798. PubMed ID: 37007633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.